A Phase 1/2 interventional study of ethosuximide and placebo comparator in Headache, Migraine, sponsored by US Department of Veterans Affairs. Terminated at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-08-19.
Sponsored by US Department of Veterans Affairs · Phase 1/2, Interventional, and Prevention
The purpose of this study is to determine whether ethosuximide works better than placebo in the prevention of episodic migraine among veterans.
Chronic and episodic headaches in veteran populations include migraine, transformed migraine, and post-traumatic headache with migrainous features. More and better prophylactic drugs with fewer side effects (such as weight gain) are needed to treat these disabling, refractory conditions which generally have less than a 50% response rate to preventative treatments.
Rare forms of severe familial hemiplegic migraine (FHM) are considered channelopathies and can be caused by mutations in a calcium channel gene. Serotonin is also known to be a critical neurotransmitter in migraine based on the pharmacology of acute and preventative treatments. We previously identified a "migraine" signaling pathway in an invertebrate C. elegans "hemiplegic migraine" model of a mutant calcium channel upstream from transforming growth factor-beta (TGF-beta) and showed that low serotonin levels can be rescued by treatment with the childhood antiepileptic drug ethosuximide (ESX).
Objective: We propose to test our findings from this invertebrate migraine model to determine its relevance to humans in the prevention of episodic migraine.
Primary Aim: Determine whether ethosuximide (ESX) will be significantly more effective than placebo in reducing migraine headache days. We propose a 3 year, double blind, phase 1/2 randomized, 2:1 ESX:placebo controlled parallel trial in episodic migraineurs comparing migraine headache days during the last 4 weeks of treatment to a pre-treatment 4 week baseline.
1,528 studies on the registry are indexed under Migraine Disorders; 299 are open to participants now.
This study's enrollment of 5 is below the median of 80 across 1,175 interventional studies indexed under Migraine Disorders.
Browse Migraine Disorders studies →US Department of Veterans Affairs is the lead sponsor of 658 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Veterans with headache must have migraine categorized using the International Headache Society (I.H.S.) criteria as illustrated below for the two main types with and without aura.
Criteria for migraine without aura (I.H.S. 1.1)
headache with two of the following characteristics
one of the following occurs with headache
Criteria for migraine with aura (I.H.S. 1.2)
at least three of the following characteristics:
One or more aura symptoms of the following types:
Aphasia or unclassifiable speech difficulty
Exclusion Criteria:
Ongoing exclusions during the study:
ethosuximide blinded capsules of 250mg ESX; titration up to 4 capsules qd (expected) or 5 or 6 capsules for efficacy (not to exceed "30mg"/kg/d) vs maximum tolerability
Drug: ethosuximide
placebo same size blinded capsules as the 250mg ESX; similar titration up to 4 capsules qd (expected) or 5 or 6 capsules for efficacy (not to exceed "30mg"/kg/d) vs maximum tolerability
Other: placebo comparator
ethosuximide (ESX)
Also known as: zarontin
placebo
Migraine Headache Days Per 4 Week Period Comparing the Last 4 Weeks of Treatment to a 4 Week Pre-treatment Baseline.
Compare number of migraine headache days pre and post treatment between the ESX and placebo group. Study terminated early-no outcome data available. The single subject assigned to study drug did not actually take it according to subsequent review of ESX drug levels.
Time frame: 4 weeks, end of treatment and pre-treatment baseline
Primary Care and Neurology Clinic prescreening and recruitment from VA Pittsburgh hospitals during the following periods: 1/14/11-4/1/11; 1/14/12-3/19/12; 2/4/13-3/12/14. Average prescreening of datawarehouse records for eligibility = 2954 subjects/month. Average prescreening electronic chart review for eligibility = 265 subjects/month.
| Milestone | Arm 1-drug Treatment | Arm 2-placebo |
|---|---|---|
| Started | 1 | 1 |
| Completed | 1 | 0 |
| Not completed | 0 | 1 |
| Withdrew: Study terminated early | 0 | 1 |
Compare number of migraine headache days pre and post treatment between the ESX and placebo group. Study terminated early-no outcome data available. The single subject assigned to study drug did not actually take it according to subsequent review of ESX drug levels.
No measurements were reported for this outcome.
Collected over 16 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1- Ethosuximide | — | 0/1 (0%) | 1/1 (100%) |
| Arm 2- Placebo Comparator | — | 0/1 (0%) | 1/1 (100%) |
| Event | Arm 1- Ethosuximide | Arm 2- Placebo Comparator |
|---|---|---|
| hiccupsRespiratory, thoracic and mediastinal disorders | 1/1 | 1/1 |
| fatigueGeneral disorders | 1/1 | 1/1 |
| diarrheaGastrointestinal disorders | 0/1 | 1/1 |
| abdominal painGastrointestinal disorders | 1/1 | 0/1 |
| somnolenceNervous system disorders | 1/1 | 0/1 |
| nauseaGastrointestinal disorders | 0/1 | 1/1 |
Enrollees who completed baseline period and randomization.
| Age, Categorical(Participants) | Arm 1 | Arm 2 | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 1 | 2 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Arm 1 | Arm 2 | Total |
|---|---|---|---|
| Female | 1 | 0 | 1 |
| Male | 0 | 1 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Arm 1 | Arm 2 | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 1 | 1 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Arm 1 | Arm 2 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 1 | 1 | 2 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Arm 1 | Arm 2 | Total |
|---|---|---|---|
| United States | 1 | 1 | 2 |
This study is terminated, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
US Department of Veterans Affairs